Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
The gut microbiome in multiple sclerosis.
[Sociological research in Samara Oblast: a role of social organizations of patients in the improvement of quality of medical and social care].
Concomitant amyotrophic lateral sclerosis and paraclinical laboratory features of multiple sclerosis: coincidence or causal relationship?
Distraction adds to the cognitive burden in multiple sclerosis.
Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.
Balance and Gait in People with Multiple Sclerosis: A Comparison with Healthy Controls and the Immediate Change after an Intervention based on the Bobath Concept.
The invisible gorilla strikes again: sustained inattentional blindness in expert observers.
SymptoMScreen: A Tool for Rapid Assessment of Symptom Severity in MS Across Multiple Domains.
Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
Regression-Based Norms Improve the Sensitivity of the National MS Society Consensus Neuropsychological Battery for Pediatric Multiple Sclerosis (NBPMS).
Life-threatening asthma attack during prolonged fingolimod treatment: case report.
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica.
CCR2+CCR5+ T Cells Producing Matrix Metalloproteinase-9 and Osteopontin in the Pathogenesis of Multiple Sclerosis.
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS
Alemtuzumab: The advantages and challenges of a novel therapy in MS.
18F-FDG PET Detects Inflammatory Infiltrates in Spinal Cord Experimental Autoimmune Encephalomyelitis Lesions.
Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system.
Blockade of CD47 ameliorates autoimmune inflammation in CNS by suppressing IL-1-triggered infiltration of pathogenic Th17 cells.
Orbital Doppler evaluation of blood flow velocities in optic neuritis.
Ginseng in the Treatment of Fatigue in Multiple Sclerosis: A Randomized Placebo-Controlled Double-Blind Pilot Study.
Dual-Task Assessment in Natalizumab-Treated Multiple Sclerosis Patients.
MRI mean diffusivity detects widespread brain degeneration in multiple sclerosis.
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study.
Spinal cord injury is related to an increased risk of multiple sclerosis: a population-based, propensity score-matched, longitudinal follow-up study.
Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS.
Pages
« first
‹ previous
…
182
183
184
185
186
187
188
189
190
…
next ›
last »